Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**caregraft** is a multi-layer graft processed using proprietary technology, designed to preserve all naturally occurring components of birth tissue, including the amnion, chorion, and intermediate (spongy) layer of the placenta. It is a dehydrated amnion and chorion membrane allograft, intended as an allogeneic matrix, cellular and tissue-based skin substitute for wound healing, especially for use as a protective barrier in acute and chronic wound care applications. The natural amniotic tissue provides mechanical protection and delivers growth factors to the wound bed, supporting the healing process. The graft is amber in color due to the preservation of placental structures, is dehydrated, packaged, terminally sterilized, and has a shelf life of 5 years stored at ambient temperature. It is CMS Red Book listed as a human cells, tissues, and cellular and tissue-based product (HCT/P), and is reimbursable for non-healing wounds[1][3][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caregraft.